New radioactive drug targets Hard-to-Treat melanoma
Disease control
Recruiting now
This early-stage trial tests an investigational drug for adults with melanoma that has spread or cannot be removed by surgery. The main goals are to find the safest dose and see what side effects occur. Participants receive the drug once every 6 weeks for up to 6 doses, along wit…
Phase: PHASE1 • Sponsor: Alpha-9 Oncology USA Inc. • Aim: Disease control
Last updated May 04, 2026 00:43 UTC